CRIS Current Research Information System

SARTOR, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.734
NA - Nord America 4.255
EU - Europa 3.436
AF - Africa 331
SA - Sud America 258
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 8
Totale 13.030
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.191
SG - Singapore 1.315
CN - Cina 1.298
VN - Vietnam 1.209
IT - Italia 795
GB - Regno Unito 734
SE - Svezia 459
DE - Germania 439
HK - Hong Kong 330
IN - India 191
NL - Olanda 183
KR - Corea 181
BR - Brasile 180
RU - Federazione Russa 154
FR - Francia 137
IE - Irlanda 128
FI - Finlandia 84
TG - Togo 82
CI - Costa d'Avorio 70
ZA - Sudafrica 62
EE - Estonia 54
SC - Seychelles 54
NG - Nigeria 53
JP - Giappone 46
BG - Bulgaria 43
CH - Svizzera 38
JO - Giordania 38
AR - Argentina 35
CA - Canada 35
UA - Ucraina 33
ID - Indonesia 31
AT - Austria 27
BE - Belgio 27
PL - Polonia 24
ES - Italia 21
MX - Messico 20
IR - Iran 17
TR - Turchia 17
BD - Bangladesh 12
GR - Grecia 10
EC - Ecuador 9
LT - Lituania 9
UZ - Uzbekistan 8
CL - Cile 7
AU - Australia 6
EU - Europa 6
IQ - Iraq 6
PE - Perù 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
MK - Macedonia 5
PK - Pakistan 5
VE - Venezuela 5
CZ - Repubblica Ceca 4
HR - Croazia 4
LB - Libano 4
RO - Romania 4
RS - Serbia 4
BY - Bielorussia 3
IL - Israele 3
MA - Marocco 3
PT - Portogallo 3
UY - Uruguay 3
AL - Albania 2
EG - Egitto 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LI - Liechtenstein 2
MY - Malesia 2
NZ - Nuova Zelanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GD - Grenada 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
JM - Giamaica 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
ML - Mali 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
PS - Palestinian Territory 1
QA - Qatar 1
SA - Arabia Saudita 1
SN - Senegal 1
SV - El Salvador 1
TM - Turkmenistan 1
Totale 13.024
Salva come PNG Salva come JPEG
Città #
Singapore 877
Southend 663
Ashburn 573
Chandler 429
Dong Ket 418
Hong Kong 326
Hefei 325
Fairfield 271
Ho Chi Minh City 210
Beijing 208
Ann Arbor 180
Seoul 179
Hanoi 168
Houston 160
Santa Clara 159
Dallas 154
Bologna 153
Wilmington 148
Woodbridge 145
Princeton 134
Dublin 128
Boardman 122
Seattle 122
Cambridge 98
Lomé 82
Milan 77
New York 71
Abidjan 70
Los Angeles 56
Westminster 55
Nanjing 52
Padova 52
Helsinki 51
Munich 48
Abeokuta 47
Medford 44
Sofia 43
Frankfurt am Main 39
Amman 38
Berlin 37
São Paulo 37
Tokyo 37
Bremen 36
Buffalo 35
Redondo Beach 35
Rome 34
Bengaluru 30
Redmond 29
Florence 28
Brussels 27
Saint Petersburg 27
Bern 26
Redwood City 26
San Diego 25
Turin 25
Jinan 24
Shenyang 24
Shanghai 23
Tianjin 22
Changsha 20
Hebei 20
Zhengzhou 20
Haiphong 19
Jakarta 19
London 19
Toronto 19
Biên Hòa 18
Falkenstein 18
Nanchang 18
Turku 18
Guangzhou 17
Ha Long 17
Jiaxing 17
Nuremberg 17
Vienna 17
Thái Nguyên 15
Phoenix 14
Stockholm 14
Chicago 13
Da Nang 13
Lappeenranta 13
Fuzhou 12
Mountain View 12
Amsterdam 11
Falls Church 11
Warsaw 11
Brooklyn 10
Casalecchio di Reno 10
Chengdu 10
Norwalk 10
Atlanta 9
Cesena 9
Hải Dương 9
Shijiazhuang 9
Tongling 9
Wuhan 9
Ankara 8
Bari 8
Chennai 8
Des Moines 8
Totale 8.320
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 628
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 278
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 232
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 226
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 222
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 218
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 215
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 211
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 206
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 201
A case report of acute myeloid leukemia and neurofibromatosis 1 198
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 197
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 193
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 189
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 185
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 183
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 179
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 168
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 168
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 162
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 159
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 159
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 158
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 157
Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study 157
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 157
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 156
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 155
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 154
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 154
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 154
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 153
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 149
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 146
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 146
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 145
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia 144
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 142
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 140
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 139
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 135
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 135
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 135
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 133
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 133
SNP array reveals a new deletion of JAK2 in AML patients 133
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia 132
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 131
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 130
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 127
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 127
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 127
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 127
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 125
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease 124
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 124
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 124
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 123
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 121
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 121
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 120
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR 118
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 118
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 117
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 117
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 114
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 112
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 109
Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience 109
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 108
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 107
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study 105
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 105
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 104
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 103
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 102
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 99
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 97
Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. 97
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 96
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 95
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents 90
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 86
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis 85
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 84
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 80
COMPARISON BETWEEN NGS IGH/TCR AND RT-PCR BCR::ABL1 MINIMAL RESIDUAL DISEASE IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY ANALYSIS 77
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin 67
Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment 63
null 52
Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule 52
null 50
Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia 46
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 45
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 35
Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment 34
Acute myeloid leukemia mutations: Therapeutic implications 34
Posterior Reversible Encephalopathy Syndrome in a B-Cell Acute Lymphoblastic Leukemia Young Adult Patient Treated with a Pediatric-like Chemotherapeutic Schedule 23
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 21
Totale 13.326
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.529
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.529
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021905 0 0 0 0 0 41 27 60 103 30 66 578
2021/20221.506 140 35 69 141 137 65 33 117 69 125 322 253
2022/20231.841 184 254 74 235 197 154 49 115 310 45 137 87
2023/2024602 16 73 38 62 38 118 43 62 31 39 53 29
2024/20252.662 113 361 212 207 245 122 268 113 48 264 209 500
2025/20263.622 620 1.159 498 483 614 248 0 0 0 0 0 0
Totale 13.326